1. Piazza GA, Chen X, Ward A, Coley A, Zhou G, Buchsbaum DJ, Maxuitenko Y, Keeton AB. Targeting cGMP/PKG signaling for the treatment or prevention of colorectal cancer with novel sulindac derivatives lacking cyclooxygenase inhibitory activity. Oncology Signaling. 2020 Volume 3; Pages 1- 6.

2. Ward AB, Keeton AB, Chen X, Mattox TE, Coley AB, Maxuitenko YY, Buchsbaum DJ, Randall TD, Zhou G, and Piazza GA. Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS. MedComm. 2020 “In Press”.

3. Piazza GA, Ward A, Chen X, Maxuitenko Y, Coley A, Aboelella NS, Buchsbaum DJ, Boyd MR, Keeton AB, and Zhou G. PDE5 and PDE10 inhibition activate cGMP/PKG signaling to block Wnt/β-catenin transcription, cancer cell growth, and tumor immunity. Drug Discovery Today. “In Press”.  Pre-proof:

4. Mattox TE, Chen X, Maxuitenko YY, Keeton AB, Piazza GA. Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers. Int J Mol Sci. 2019;21(1):141. Published 2019 Dec 24. PMID: 31878223

5. Keeton AB, Salter EA, Piazza GA. The RAS-Effector Interaction as a Drug Target. Cancer Res. 2017;77(2):221-226. PMID: 28062402

6. Adam B. Keeton and Gary A. Piazza. 2016. Chapter 8 – Search for Inhibitors of Ras-Driven Cancers, Pages 135-154 in Conquering RAS, 1st Edition. From Biology to Cancer Therapy. Edited by A. Azmi. 2016, ISBN: 978-0-1280-3505-4. Academic Press, Elsevier, Cambridge, MA, USA.